
|Videos|October 19, 2018
Overcoming BTK Inhibitor Resistance in NHL
Author(s)Julie M. Vose, MD, MBA
Julie M. Vose, MD, MBA, discusses resistance to BTK inhibitors in patients with non-Hodgkin lymphoma.
Advertisement
Julie M. Vose, MD, MBA, professor, internal medicine, chief, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses resistance to BTK inhibitors in patients with non-Hodgkin lymphoma.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5










































